

E-5 (Rev. 10/01/02)

~~16.~~⁴ (Currently amended) A method for ~~treating~~ reducing inflammation in an animal having inflammation, comprising administering to the animal an effective amount of a composition comprising *Mycobacterium phlei*-DNA preserved and complexed on a *Mycobacterium phlei* cell wall (MCC) and a pharmaceutically acceptable carrier, wherein the amount is effective to ~~treat~~ reduce the inflammation.

~~17. (Cancel)~~

~~18.~~⁵ (Original) The method of Claim ~~16~~⁴, wherein the effective amount is effective to induce the synthesis of cytokine IL-10.

~~19. (Cancel)~~

~~20.~~⁶ (Original) The method of Claim ~~16~~⁴, wherein the pharmaceutically acceptable carrier is selected from the group consisting of a liquid carrier and a solid carrier.

~~21-23. (Cancel)~~

~~24.~~⁷ (Previously Presented) The method of Claim 1, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.

~~25.~~⁸ (Previously Presented) The method of Claim ~~2~~, wherein the mycobacterial deoxyribonucleic acid and the mycobacterial cell wall are obtained from *Mycobacterium phlei*.

~~26. (Cancel)~~

~~27. (Cancel)~~